C
Cybin Inc. (HELP)
NGM – Real Time Price. Currency in USD
5.06
-0.04 (-0.78%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
5.06
-0.04 (-0.78%)
At close: May 12, 2026, 4:00 PM EDT
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
| Name | Position |
|---|---|
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Mr. Aaron Bartlone | Chief Operating Officer |
| Mr. Eric So L.L.B. | Co-Founder, Interim CEO, President & Executive Chairman |
| Mr. Gabriel Fahel | Chief Legal Officer & Corporate Secretary |
| Mr. George Tziras | Chief Business Officer |
| Mr. Greg Cavers | Chief Financial Officer |
| Mr. John Kanakis | Co-Founder |
| Mr. Paul Glavine | Co-Founder, Chief Growth Officer & Director |
| Ms. Lori Challenger | Chief Compliance, Ethics & Administrative Officer |
| Sara Brittany Somerset | Chief Communications Officers |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | 6-K | cybininc-form6xk05x04x2026.htm |
| 2026-04-28 | 6-K | cybininc-form6xk04x28x2026.htm |
| 2026-04-23 | 6-K | cybininc-form6xk04x23x2026.htm |
| 2026-04-20 | 6-K | cybininc-form6xk04x20x2026a.htm |
| 2026-04-16 | 6-K | cybininc-form6xk04x16x2026.htm |
| 2026-03-23 | D | |
| 2026-03-12 | 6-K | cybininc-form6xk03x12x2026.htm |
| 2026-03-05 | 6-K | form6k.htm |
| 2026-02-24 | 6-K | cybininc-form6xk02x24x2026.htm |
| 2026-02-18 | 6-K | cybin-mcrxform6xkxfebruary.htm |